Biology Reference
In-Depth Information
Manabe H, Akuta K, Sejimo H, Kawasaki H, Nukui E, Ichimura M, Kase H, Kawakita T, Suzuki F,
Kitamura S, Sato S, Ohmori K (1997) Anti-inflammatory and bronchodilator properties of
KF19514, a phosphodiesterase 4 and 1 inhibitor. Eur J Pharmacol 332:97-107
Martin JG, Duguet A, Eidelman DH (2000) The contribution of airway smooth muscle to airway
narrowing and airway hyperresponsiveness in disease. Eur Respir J 16:349-354
Massaad C, Houard N, Lombes M, Barouki R (1999) Modulation of human mineralocorticoid
receptor function by protein kinase A. Mol Endocrinol 13:57-65
McKay LI, Cidlowski JA (1999) Molecular control of immune/inflammatory responses: interac-
tions between nuclear factor-
k
B and steroid receptor-signaling pathways. Endocr Rev 20:
435-459
Meja K, Catley MC, Cambridge LM, Barnes PJ, Lum H, Newton R, Giembycz MA (2004)
Adenovirus-mediated delivery and expression of a cAMP-dependent protein kinase
inhibitor gene to BEAS-2B epithelial cells abolishes the anti-inflammatory effects of roli-
pram, salbutamol and prostaglandin E
2
: a comparison with H-89. J Pharmacol Exp Ther
309:833-844
Meliton AY, Munoz NM, Liu J, Lambertino AT, Boetticher E, Myo S, Myou S, Zhu X, Johnson
M, Leff AR (2003) Blockade of LTC
4
synthesis caused by additive inhibition of gIV-PLA
2
phosphorylation: Effect of salmeterol and PDE4 inhibition in human eosinophils. J Allergy
Clin Immunol 112:404-410
Meliton AY, Munoz NM, Lambertino A, Boetticher E, Learoyd J, Zhu X, Leff AR (2006)
Phosphodiesterase 4 inhibition of
b
2-integrin adhesion caused by leukotriene B
4
and TNF
a
in human neutrophils. Eur Respir J 28:920-928
Michaeli T, Bloom TJ, Martins T, Loughney K, Ferguson K, Riggs M, Rodgers L, Beavo JA,
Wigler M (1993) Isolation and characterization of a previously undetected human cAMP
phosphodiesterase by complementation of cAMP phosphodiesterase-deficient
Saccharomyces
cerevisiae
. J Biol Chem 268:12925-12932
Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S (2002) Oral sildenafil is an
effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension:
comparison with inhaled nitric oxide. Circulation 105:2398-2403
Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, Wang SH, Modry D,
Archer SL (2003) Long-term treatment with oral sildenafil is safe and improves functional
capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 108:
2066-2069
Miller AH, Vogt GJ, Pearce BD (2002) The phosphodiesterase type 4 inhibitor, rolipram, enhances
glucocorticoid receptor function. Neuropsychopharmacology 27:939-948
Mittelstadt PR, Ashwell JD (2001) Inhibition of AP-1 by the glucocorticoid-inducible protein
GILZ. J Biol Chem 276:29603-29610
Movsesian MA (2003) PDE3 inhibition in dilated cardiomyopathy: reasons to reconsider. J Card
Fail 9:475-480
Myou S, Fujimura M, Kamio Y, Ishiura Y, Tachibana H, Hirose T, Hashimoto T, Matsuda T (1999)
Bronchodilator effect of inhaled olprinone, a phosphodiesterase 3 inhibitor, in asthmatic
patients. Am J Respir Crit Care Med 160:817-820
Naeije R (2003) Pulmonary hypertension and right heart failure in COPD. Monaldi Arch Chest Dis
59:250-253
Naeije R, Barbera JA (2001) Pulmonary hypertension associated with COPD. Crit Care 5:
286-289
Nakata A, Ogawa K, Sasaki T, Koyama N, Wada K, Kotera J, Kikkawa H, Omori K, Kaminuma O
(2002) Potential role of phosphodiesterase 7 in human T cell function: comparative effects of
two phosphodiesterase inhibitors. Clin Exp Immunol 128:460-466
Newton R (2000) Molecular mechanisms of glucocorticoid action: what is important? Thorax 55:
603-613
Newton R, Holden NS (2007) Separating transrepression and transactivation: a distressing divorce
for the glucocorticoid receptor? Mol Pharmacol 72:799-809
